Fibroblast growth factors are therapeutic targets for radiofrequency ablation induced tumorigenesis

bioavailability.Here, we evaluate in a rat model the possible benefit against HF of encapsulated Gly in polymeric nanomicelles based on polygalacturonic acid and polyacrylic acid (Gly-NMs) previously characterized and known to increase drug bioavailability.Method: Gly and Gly-NMs role against fibrosis were tested in a CCl4induced HF rat model.Morphological, hematic and hepatic data were collected to monitor disease progression.Results: In terms of body weight, liver weight, and serum parameters of hepatic function, Gly-NM appeared to provide better recovery from hepatic fibrosis than Gly.Molecular markers and histopathological analysis showed that Gly-MN demonstrated marked antifibrotic properties, reducing collagen deposition in liver tissue and decreasing the activation of hepatic stellate cells.Furthermore, we remarked an improved CCl 4 -induced fatty-degeneration following Gly-MNs treatment.The latter was associated with a gene downregulation of carnitine palmitoyl-transferase 1A (Cpt1a) which can impose a protective action against CCl 4 insult as reported in the literature for mice lacking the enzyme. Conclusion:Our results show that encapsulated Gly reduces fibrosis and related disease markers and improve the fatty degeneration better than free drug in a in vivo rat model.